"With these new rules, for the first time in its history the regulation of medicines has moved away from science and away from clear information for the public. The College is deeply alarmed by these developments… the endorsement of such therapies without appropriate pre-clinical tests and clinical trials and without rigorous safety and efficacy data may encourage patients to use them as an alterative to conventional treatments. We do not believe that this is in the patient's best interests." Professor Adrian Newland, President, The Royal College of Pathologists (22nd October 2006) [pdf]